TABLE 1.
Characterization of the well-documented anti-HIV-1 Env nAbs and non-nAbsa
| nAbs and non-Abs | Antigen (epitope) | Isotype | Neutralizing activity | Isolated from HIV-1 clade | Reference(s) |
|---|---|---|---|---|---|
| nAbs | |||||
| 2G12 | gp120 (C3/V4 domain) | IgG1, κ | Yes | B | 20, 36–39 |
| 2F5 | gp41 (ELDKWAS) | IgG1, κ | Yes | B | 36, 40, 41 |
| 4E10 | gp41 (NVVFDIT) | IgG1, κ | Yes | B | 19 |
| Non-nAbs | |||||
| 2.2C | gp120 | IgG1, κ | No | B | 43, 44 |
| A32 | gp120 (E/K)VGKAMYAPP | IgG1, λ | No | B | 20, 44–46 |
| N5-i5 | gp120 | IgG1, λ | No | B | 44 |
| N12-i15 | gp120 | IgG1, κ | No | B | 44 |
a
All nAbs were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 2G12, 2F5, and 4E10 were all from H. Katinger. All non-nAbs were obtained from Y. Guan at the University of Maryland and J. Robinson at Tulane University.